Making quality-of-life results more meaningful for clinicians

The Lancet

Volumn 371, Issue 9614, 2008, Pages 709-710

  King, Madeleine T ^a   Fayers, Peter M ^b,c  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; HEALTH CARE PERSONNEL; MEDICAL INFORMATION; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITY OF LIFE; STUDENT T TEST;

EID: 39649104124     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60324-4     Document Type: Note

References (12)

1. Johnson J., and Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69 (1985) 1155-1159
2. Clinical Trials Cooperative Group Program. Cancer therapy evaluation program: guidelines (1988), Division of Cancer Treatment, National Cancer Institute, Bethesda MD, USA
3. Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual Life Res 1 (1992) 211-218
4. MRC. Guidelines for good clinical practice in clinical trials (1998). http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC002416 (accessed Sept 12, 2007).
5. National Health and Medical Research Council. The virtuous cycle: working together for health and medical research. Health and medical research strategic review discussion document (December, 1998). http://www.health.gov.au/internet/wcms/publishing.nsf/content/hmrsr.htm (accessed Sept 12, 2007).
6. Fayers P., and Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer 38 (2002) S125-S133
7. Guyatt G., and Schünemann H. How can quality of life researchers make their work more useful to health workers and their patients?. Qual Life Res 16 (2007) 1097-1105
8. Fayers P., and Machin D. Quality of Life: Assessment, Analysis and Interpretation (2000), Wiley & Sons, Chichester, UK 325
9. Osoba D., Bezjak A., Brundage M., and for the Quality of Life committee of the NCIC CTG. Analysis and interpretation of health-related quality of life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41 (2005) 280-287
10. Wisløff F., Hjorth M., Kaasa S., and for the Nordic Myeloma Study Group. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + α-interferon. Br J Haematol 94 (1996) 324-332
11. Fayers P., Aaronson N., Bjordal K., Groenvold M., Curran D., and Bottomley A. EORTC QLQ-C30 scoring manual. 3rd edn. (2001), European Organization for Research and Treatment of Cancer, Brussels
12. Schünemann H., Akl E., and Guyatt G. Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. Health Qual Life Outcomes 4 (2006) 62